---
title: "Wegovy (semaglutide) in chronic weight management: Dosing and administration questions"
description: "Dosing and administration questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, and Prescribing. Questions: What is the Wegovy injection dosing schedule? What is the Wegovy pill dosing schedule? When can the Wegovy dose be increased to 7.2 mg (Wegovy HD)? What if a patient cannot tolerate Wegovy HD 7.2 mg? 9 further questions follow. 13 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Dosing and administration questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Dosing and administration questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications: Dosing and administration](https://www.evicenter.com/medical-information/wegovy/dosing-and-administration).

## Dosing

<a id="wegovy-injection-dosing-schedule"></a>

### What is the Wegovy injection dosing schedule?

> “The recommended starting dosage of WEGOVY<sup>®</sup> injection is 
> 0.25 mg administered subcutaneously once weekly.
> •	Follow the dosage escalation in Table 1 to reduce the risk 
> of gastrointestinal adverse reactions [see Warnings and 
> Precautions (5.6), Adverse Reactions (6.1)].
> •	If patients do not tolerate a dose during dosage escalation, 
> consider delaying dosage escalation for 4 weeks.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Table 1. Recommended Starting Dosage and Dosage 
> Escalation of WEGOVY<sup>®</sup> Injection for All Approved 
> Indications in Adults and Pediatric Patients Aged 12 
> Years and Older”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Weeks
> Once-weekly 
> Subcutaneous 
> Injection Dosage
> Starting 
> Dosage
> 1 through 4
> 0.25 mg
> Dosage
> Escalation
> 5 through 8
> 0.5 mg
> 9 through 12
> 1 mg
> 13 through 16
> 1.7 mg
> Maintenance
> Dosage
> 17 and onward
> See the indication below 
> for the recommended 
> maintenance dosage(s)”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Weight Reduction in Adults
> •	The maintenance dosage of WEGOVY<sup>®</sup> for weight reduction 
> in adults is either 1.7 mg or 2.4 mg (recommended) injected 
> subcutaneously once weekly.
> •	For patients who tolerate the 2.4 mg dosage for at least 4 
> weeks and additional weight reduction is clinically indicated, 
> the dosage may be increased to a maximum dosage of 7.2 mg 
> subcutaneously once weekly.
> •	Consider treatment response and tolerability when selecting 
> the maintenance dosage [see Adverse Reactions (6.1), 
> Clinical Studies (14.2)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

Note: The Table 1 cells follow its title in the label text, after the MASH maintenance dosage paragraph that sits beside the table on the page.

<a id="wegovy-pill-dosing-schedule"></a>

### What is the Wegovy pill dosing schedule?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “Recommended Dosage of WEGOVY<sup>®</sup> Tablets for Cardiovascular 
> Risk Reduction or Weight Reduction in Adults
> •	The recommended starting dosage of WEGOVY<sup>®</sup> tablets is 
> 1.5 mg taken orally once daily. Follow the dosage escalation 
> in Table 2 to reduce the risk of gastrointestinal adverse 
> reactions [see Warnings and Precautions (5.6), Adverse 
> Reactions (6.1)].
> •	If patients do not tolerate a dose during dosage escalation, 
> consider delaying dosage escalation.
> •	The recommended maintenance dosage of WEGOVY<sup>®</sup> tablets 
> is 25 mg orally once daily.
> •	If patients do not tolerate the 25 mg once daily maintenance 
> dosage, consider switching to WEGOVY<sup>®</sup> injection 1.7 mg 
> once weekly [see Dosage and Administration (2.5)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Table 2. Recommended Dosage of WEGOVY<sup>®</sup> 
> Tablets for Cardiovascular Risk Reduction or Weight 
> Reduction in Adults”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Days
> Once Daily Tablet 
> Dosage
> Starting Dosage
> 1 through 30
> 1.5 mg
> Dosage Escalation
> 31 through 60
> 4 mg
> 61 through 90
> 9 mg
> Maintenance Dosage
> 91 and onward
> 25 mg”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

Note: The Table 2 cells follow the dosage forms table in the label text.

<a id="wegovy-wegovy-hd-when"></a>

### When can the Wegovy dose be increased to 7.2 mg (Wegovy HD)?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “For patients who tolerate the 2.4 mg dosage for at least 4 
> weeks and additional weight reduction is clinically indicated, 
> the dosage may be increased to a maximum dosage of 7.2 mg 
> subcutaneously once weekly.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

<a id="wegovy-hd-not-tolerated"></a>

### What if a patient cannot tolerate Wegovy HD 7.2 mg?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “For patients taking Wegovy<sup>®</sup> HD, if patients do not tolerate the 7.2 mg dosage, consider reducing the dose to 2.4 mg.<sup>1</sup> Consider treatment response and tolerability when selecting the maintenance dosage.”

Source: [WEGOVY: Frequently Asked Questions, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html#:~:text=For%20patients%20taking,when%20selecting%20the%20maintenance%20dosage.)

This passage is in a collapsed section of the page; select: What if my patients cannot tolerate Wegovy® HD?

<a id="wegovy-maximum-dose"></a>

### What is the maximum dose of Wegovy for weight loss in adults?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Weight Reduction in Adults
> •	The maintenance dosage of WEGOVY<sup>®</sup> for weight reduction 
> in adults is either 1.7 mg or 2.4 mg (recommended) injected 
> subcutaneously once weekly.
> •	For patients who tolerate the 2.4 mg dosage for at least 4 
> weeks and additional weight reduction is clinically indicated, 
> the dosage may be increased to a maximum dosage of 7.2 mg 
> subcutaneously once weekly.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

<a id="wegovy-missed-dose-pill"></a>

### What if a Wegovy pill dose is missed?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “If a dose of WEGOVY<sup>®</sup> tablets is missed, skip the missed dose and 
> take the next dose the following day.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Do not take more than one tablet per day.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

<a id="wegovy-switch-pen-pill"></a>

### How do you switch between the Wegovy injection and the Wegovy pill?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “2.5	 Switching Between WEGOVY<sup>®</sup> Injection and 
> WEGOVY<sup>®</sup> Tablets
> Switching from WEGOVY<sup>®</sup> Injection to WEGOVY<sup>®</sup> Tablets
> •	Patients taking WEGOVY<sup>®</sup> 2.4 mg injection for cardiovascular 
> risk reduction or weight reduction in adults may switch to 
> WEGOVY<sup>®</sup> 25 mg tablets.
> •	One week after discontinuing WEGOVY<sup>®</sup> 2.4 mg injection, 
> initiate 25 mg of WEGOVY<sup>®</sup> tablets orally once daily.
> Switching from WEGOVY<sup>®</sup> Tablets to WEGOVY<sup>®</sup> Injection
> •	Patients may switch from WEGOVY<sup>®</sup> 25 mg tablets to 
> WEGOVY<sup>®</sup> injection.
> •	The day after discontinuing WEGOVY<sup>®</sup> tablets 25 mg once 
> daily, initiate WEGOVY<sup>®</sup> 2.4 mg subcutaneous injection once 
> weekly. For patients who do not tolerate WEGOVY<sup>®</sup> 25 mg 
> tablets, consider switching to WEGOVY<sup>®</sup> 1.7 mg injection.
> •	If additional weight reduction is needed in patients with type 
> 2 diabetes mellitus treated with WEGOVY<sup>®</sup> 25 mg tablets, 
> consider switching to WEGOVY<sup>®</sup> 1.7 mg injection and follow 
> the recommended dosage escalation for WEGOVY<sup>®</sup> injection. 
> [see Dosage and Administration (2.2), Use in Specific 
> Populations (8.6), Clinical Pharmacology (12.3)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

## Administration

<a id="wegovy-how-to-take-pill"></a>

### How should the Wegovy pill be taken?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “•	Take one WEGOVY<sup>®</sup> tablet orally once daily on an empty 
> stomach in the morning with water (up to 4 ounces). Do not 
> take WEGOVY<sup>®</sup> tablets with other liquids besides water [see 
> Clinical Pharmacology (12.3)].
> •	Do not take more than one tablet per day.
> •	Swallow tablets whole. Do not split, crush, chew or dissolve 
> in any solution.
> •	After taking a WEGOVY<sup>®</sup> tablet, wait at least 30 minutes 
> before eating food, drinking beverages or taking other oral 
> medications [see Clinical Pharmacology (12.3)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

<a id="wegovy-pill-30-minute-wait"></a>

### Why wait 30 minutes after taking the Wegovy pill?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “Waiting 30 minutes is critical for the absorption of the active ingredient, semaglutide. Food, drink, or other medications can significantly decrease the absorption of the Wegovy<sup>®</sup> pill, reducing its effectiveness.”

Source: [WEGOVY: Wegovy® Pen and Pill Information, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/the-wegovy-pen-pill.html#:~:text=Waiting%2030%20minutes%20is%20critical,pill%2C%20reducing%20its%20effectiveness.)

On the page, select: Pill, then Why do patients need to wait 30 minutes after taking the pill before they can eat or drink?

> “Effect of Volume and Timing of Water Consumption: Single doses of oral semaglutide tablet were 
> administered with 50 mL or 240 mL of water after an 8-hour overnight fast and a continued fast of 4 
> hours post-dose in healthy subjects. Semaglutide absorption [i.e., area under the curve (AUC) and peak 
> concentrations (Cmax)] was higher following dosing with 50 mL water compared to that of 240 mL water.
> For 10 days, healthy subjects received once daily doses of oral semaglutide with 50 mL or 120 mL 
> of water under fasting conditions with post-dose fasting period of 15, 30, 60, or 120 minutes. In 
> this study, semaglutide absorption (i.e., AUC and Cmax) was higher after a longer post-dose fasting 
> period. There were no clinically significant differences in semaglutide absorption with administration 
> of 50 mL or 120 mL of water.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

Note: The first passage is from a Pill tab FAQ of the administration page of the Wegovy HCP site.

<a id="wegovy-how-to-inject"></a>

### How and where is the Wegovy injection given?

> “Administer WEGOVY<sup>®</sup> injection once weekly, on the same 
> day each week, at any time of day, with or without meals.
> •	Inject WEGOVY<sup>®</sup> subcutaneously in the abdomen, thigh, 
> or upper arm. The time of day and the injection site can be 
> changed without the need for a dosage modification.
> •	Rotate injection sites with each dose.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, 
> thigh, or upper arm.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “The injection should take about 5-10 seconds. Tell patients they will hear 2 clicks during the injection. Direct patients not to stop applying pressure after the 2 clicks”

Source: [WEGOVY: Wegovy® Pen and Pill Information, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/the-wegovy-pen-pill.html#:~:text=The%20injection%20should%20take%20about,pressure%20after%20the%202%20clicks)

> “If they have problems injecting, change to a firmer injection site, such as upper leg or upper arm, or consider standing up while injecting into the lower stomach.”

Source: [WEGOVY: Wegovy® Pen and Pill Information, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/the-wegovy-pen-pill.html#:~:text=If%20they%20have%20problems%20injecting%2C,injecting%20into%20the%20lower%20stomach.)

<a id="wegovy-forms-strengths"></a>

### What forms and strengths does Wegovy come in?

> “•	Injection (3):
> 	 •	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 
> 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL 
> (WEGOVY<sup>®</sup> HD) in a single-dose pen
> 	 •	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 
> mg/0.75 mL, or 2.4 mg/0.75 mL in a single-dose syringe
> 	 •	9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use 
> pen (WEGOVY<sup>®</sup> FlexTouch<sup>®</sup>) that delivers four 2.4 mg/0.75 
> mL doses
> •	Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg (3)”

Source: [WEGOVY: Prescribing information, page 1, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=1)

> “Wegovy<sup>®</sup> pen comes in 6 packs (1 for each strength). Each pack contains 4 Wegovy<sup>®</sup> pens (1 for each week)”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=pen%20comes%20in%206%20packs,pens%20%281%20for%20each%20week%29)

> “The Wegovy<sup>®</sup> pill comes in 4 different strengths. Each bottle contains 30 Wegovy<sup>®</sup> pills (1 for each day)”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=pill%20comes%20in%204%20different,pills%20%281%20for%20each%20day%29)

On the page, select: Pill

> “WEGOVY<sup>®</sup> FlexTouch<sup>®</sup> is not recommended for self-
> administration by those who are visually impaired.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “WEGOVY<sup>®</sup> FlexTouch<sup>®</sup> must never be shared between patients, 
> even if the needle is changed. Pen-sharing poses a risk for 
> transmission of blood-borne pathogens.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

## Prescribing

<a id="wegovy-how-to-prescribe"></a>

### How is Wegovy prescribed?

> “Important to Remember:
>
> A new prescription is required for each dose strength”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=Important%20to%20Remember%3A,required%20for%20each%20dose%20strength)

> “If patients receive a starter kit that includes four 0.25 mg Wegovy<sup>®</sup> pens, check the “samples given” box in their electronic health record
>
> Write prescription for 0.5 mg
> For those who do not receive a sample, write a prescription for 0.25 mg”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=If%20patients%20receive%20a%20starter,a%20prescription%20for%200.25%20mg)

> “After your patients reach their maintenance dose, you can consider a 3-month Rx”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=After%20your%20patients%20reach%20their,can%20consider%20a%203%2Dmonth%20Rx)

> “<sup>†</sup>A 3-month supply for appropriate patients would be dispensed as 3 packs, each containing 4 Wegovy<sup>®</sup> 1.7 mg, 2.4 mg, or 7.2 mg dose singe-use pens (1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL), for a total dispense quantity of 9 mL. Days of supply: 84, dispense quantity: 9 mL. Recommended sig: Inject 1.7 mg, 2.4 mg, or 7.2 mg SUBQ once weekly for 12 weeks (84 days).”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=3%2Dmonth%20supply%20for%20appropriate%20patients,for%2012%20weeks%20%2884%20days%29.)

<a id="wegovy-needles-prescription"></a>

### Does Wegovy need a separate prescription for needles?

> “Integrated needle means no separate Rx or co-pay”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=Integrated%20needle%20means%20no%20separate%20Rx%20or%20co%2Dpay)

> “Always remove and safely discard the needle after each injection. 
> Store the WEGOVY<sup>®</sup> FlexTouch<sup>®</sup> single-patient-use pen without an injection needle attached. Always 
> use a new needle for each injection.”

Source: [WEGOVY: Prescribing information, page 17, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=17)

Note: The no-separate-needle statement concerns the single-dose pen; the Prescribing Information directs FlexTouch users to attach a new needle for each injection. The captured pages do not state whether FlexTouch needles require a separate prescription.

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations)
- [Access and coverage](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage)
